Hey Investor, Welcome to Weekly Picks, where each week our analysts hand pick their favorite Narratives from the community (what is a Narrative?). This week’s picks cover: 📈 Why now might be an opportune time to consider ASML. 🏨 How Wyndham Hotels' loyalty revenue and global expansion are driving growth. 💊 Why Novo Nordisk's risk/reward case is better than it seems. |
|
|
Why Now is the Time to buy ASML |
ASML’s monopoly on EUV tools secures long-term chip demand while its strong backlog and recurring service revenue provide earnings stability. The recent share price weakness offers a rare buying opportunity for a company essential to the future of computing. |
|
|
~30.1% undervalued vs current price |
Based on ~15% p.a. Revenue growth for 5 years | | |
|
💡 Why we like it: This narrative is a tight, well-balanced pitch that blends technical context with market timing. Instead of ignoring the selloff, they lean into it, framing the stock dip as a rare opportunity in an otherwise solid long-term story. We think the narrative strikes the right tone of measured, informed, and actionable. |
| |
Wyndham Continues Global Expansion with 19% Ancillary Revenue Growth |
Wyndham’s global expansion and asset-light model drive consistent room and ancillary revenue growth, with a robust pipeline supporting future earnings. Growing loyalty membership and strong share buybacks reinforce value, while raised guidance highlights management’s confidence in continued outperformance. |
|
|
~20.1% undervalued vs current price |
Based on ~13% p.a. Revenue growth for 3 years | | |
|
💡 Why we like it: This is a refreshingly boots-on-the-ground narrative that builds from personal experience to a full investment case. Zwfis weaves operational context, recent earnings, and valuation math into a compelling long-term outlook, while also highlighting under-appreciated levers like loyalty-driven ancillary revenue. It's personal, well-researched, and has plenty of conviction. |
|
|
A Quality Compounder Marked Down on Overblown Fears |
Novo Nordisk’s shares have dropped on pipeline, pricing, and policy fears, but its high profitability, durable intellectual property, and innovation pipeline position it for long-term growth. Current valuation ignores potential from late-stage and emerging drugs, setting up substantial upside if even one delivers. Expectations are low, yet the company’s robust GLP-1 franchise and new launches support a compelling risk/reward. |
|
| ~59.6% undervalued vs current price |
Based on ~15% p.a. Revenue growth for 10 years |
| |
|
💡 Why we like it: We love a classic contrarian setup. Here bactrian makes the case that a best-in-class compounder has been marked down on fears that appear priced for disaster rather than a cyclical reset. The narrative does a great job breaking down both the bear case (guidance cut, semaglutide saturation, policy risk) and why it’s likely overdone, given Novo’s world-class margins, strong pipeline, and low multiple. The sum-of-the-parts logic and reset expectations create a compelling upside case. |
|
|
What's next?
1. 🔔 Know when to act: Set the narrative valuations as your own fair value to know when to buy, hold or sell the stock.
2. 🤔 Get answers: Ask the author any questions in the comments section. Feel free to like as well to support their work.
3. ✨ Discover more Narratives: There are hundreds of other insightful stock narratives on our Community page.
4. ✍️ Build an audience: Have your narrative seen by millions of investors, simply meet our Featuring criteria to go into the running! |
|
|
| This email is from Simply Wall Street Pty Ltd
Level 5, 320 Pitt St Sydney 2000, NSW, Australia. Simply Wall St has no position in the company(s) mentioned. These narratives are general in nature and explore scenarios and estimates created by the authors. These narratives do not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company’s future performance and are exploratory in the ideas they cover. The fair value estimates are for informational purposes only and do not constitute a recommendation to buy or sell any stock. They do not take into account your objectives or financial situation. Note that the author’s analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this email/website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us. Privacy Policy Terms and Conditions
Don’t want to get Weekly Pick emails? Click here to stop receiving it.
Want to stop receiving emails or want to check which email you are subscribed on? Click here to manage your email subscriptions. | | |
|
|
|
